证券代码：300254 证券简称：仟源医药 公告编号：2026-010 山西仟源医药集团股份有限公司 独立董事候选人声明与承诺 声明人黄栋先生作为山西仟源医药集团股份有限公司第六届董事会独立 董事候选人，已充分了解同意由提名人山西仟源医药集团股份有限公司提名为 山西仟源医药集团股份有限公司第六届董事会独立董事候选人。现公开声明和 保证，本人与该公司之间不存在任何影响本人独立性的关系，且符合相关法律、 行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选 人任职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过山西仟源医药集团股份有限公司第五届董事会提名委员 会资格审查，提名人与本人不存在利害关系或者其他可能影响独立履职情形的 密切关系。 是 □ 否 如否，请详细说明：______________________________ 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担 任公司董事的情形。 是 □ 否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易 所业务规则规定 ...

证券代码：300254 证券简称：仟源医药 公告编号：2026-011 独立董事候选人声明与承诺 山西仟源医药集团股份有限公司 如否，请详细说明：______________________________ 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担 任公司董事的情形。 是 □ 否 声明人武进锋先生作为山西仟源医药集团股份有限公司第六届董事会独 立董事候选人，已充分了解同意由提名人山西仟源医药集团股份有限公司提名 为山西仟源医药集团股份有限公司第六届董事会独立董事候选人。现公开声明 和保证，本人与该公司之间不存在任何影响本人独立性的关系，且符合相关法 律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事 候选人任职资格及独立性的要求，具体声明并承诺如下事项： 如否，请详细说明：______________________________ 一、本人已经通过山西仟源医药集团股份有限公司第五届董事会提名委员 会资格审查，提名人与本人不存在利害关系或者其他可能影响独立履职情形的 密切关系。 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易 所业务规则规定的独立董事 ...

证券代码：300254 证券简称：仟源医药 公告编号：2026-015 山西仟源医药集团股份有限公司 关于召开2026年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 经山西仟源医药集团股份有限公司（以下简称"公司"）第五届董事会第三 十六次会议审议通过《关于召开公司 2026 年第一次临时股东会的议案》，公司决 定于 2026 年 1 月 29 日（星期四）召开公司 2026 年第一次临时股东会。现将会 议有关事项通知如下： 一、召开会议基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：公司第五届董事会 3、会议召开的合法性及合规性：董事会召开本次股东会会议符合《公司法》、 《证券法》、《深圳证券交易所创业板股票上市规则》、《上市公司股东会规则》 等有关法律、法规、规则以及《公司章程》的规定。 4、会议召开日期和时间： 现场会议召开时间：2026 年 1 月 29 日（星期四）下午 2:30 网络投票时间为： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为 2026 年 1 月 29 日 9:15- ...

证券代码：300254 证券简称：仟源医药 公告编号：2026-002 山西仟源医药集团股份有限公司 第五届董事会第三十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山西仟源医药集团股份有限公司（以下简称"公司"）于 2026 年 1 月 10 日以邮件方式发出第五届董事会第三十六次会议通知及议案，2026 年 1 月 13 日 以通讯表决的方式召开本次会议。本次会议由董事长黄乐群先生主持，应出席董 事 9 名，实际出席董事 9 名。出席会议人员对本次会议的召集、召开方式无异议。 本次会议的召集、召开符合《公司法》《公司章程》和《董事会议事规则》的有 关规定。 二、董事会会议审议情况 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以投票表决 方式通过以下议案： 1、审议通过《关于变更注册资本、修订<公司章程>并办理工商变更登记的议案》 根据《深圳证券交易所创业板股票上市规则》（2025 年修订）、《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作（2025 年修订）》 等法律、法规、 ...

Group 1 - Lichong Group expects a net profit of 830 million to 870 million yuan for 2025, representing a year-on-year growth of 17.38% to 23.04% [1] - Shandong Zhanggu anticipates a net profit of 72 million to 80 million yuan for 2025, with a year-on-year increase of 0.65% to 11.83% [2] - Yinglian Co. forecasts a net profit of 32 million to 42 million yuan for 2025, marking a turnaround from a loss of 39.67 million yuan in the previous year [3] Group 2 - Hangya Technology announces plans for shareholders to reduce their holdings by up to 2.76% of the company's shares [4] - Guizhou Tire plans to invest in a project in Morocco to produce 6 million semi-steel radial tires annually, with a total investment of 299 million USD [5] - Laisentongling's shareholder plans to reduce their stake by no more than 1% [6] Group 3 - ST Yifei's shareholder intends to reduce their holdings by up to 1.53% [7] - Hengyi Petrochemical has fully launched the second phase of its Brunei refining project, aiming for a production capacity of 12 million tons per year [8] - Zai Sheng Technology's controlling shareholder has terminated an agreement to transfer part of the company's shares [9] Group 4 - Sry New Materials proposes a cash dividend of 0.4 yuan per 10 shares for the first three quarters of 2025 [10] - Quanyin High-Tech announces that the offer period for China Seed Group's acquisition has expired, leading to a temporary suspension of its stock [11] - Zhonggang Luonai's shareholder plans to reduce their stake by up to 1% [12] Group 5 - Nanmo Bio expects to receive a government subsidy of 5.8 million yuan for its subsidiary [13] - Beite Technology has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [14] - Qianyuan Pharmaceutical's subsidiary has obtained drug registration certificates for a new medication [15] Group 6 - Boto Integrated plans to reduce its holdings by no more than 1% [16] - Wanze Co. intends to reduce its stake by up to 1.66% [17] - Tianci Materials will halt production for maintenance on its lithium hexafluorophosphate production line starting March 1, 2026 [18] Group 7 - Haopeng Technology plans to raise up to 800 million yuan through a private placement [20] - Yisheng Co. reports a 43.32% year-on-year increase in sales revenue for its white feather broiler chicks in December 2025 [21] - Jinyu Medical proposes a cash dividend of 8.8 yuan per 10 shares for the first three quarters of 2025 [22] Group 8 - Caesar Travel's subsidiary has won a management service project for the Qingdao International Cruise Port [23] - Kelun Pharmaceutical plans to repurchase shares worth 50 million to 100 million yuan [24] - Jiangling Motors reports a 10.56% year-on-year increase in cumulative sales for 2025 [25] Group 9 - Yilian Technology plans to issue convertible bonds to raise up to 1.2 billion yuan [26] - Shaanxi Guotou A intends to participate in a capital increase for Chang'an Bank, with an amount not exceeding 800 million yuan [27] - Oupokang Vision has obtained a production license for eye drops [28] Group 10 - Shanghai Electric plans to provide management services for overseas assets of China Electric International [30] - Yingfang Micro is planning a major asset restructuring, leading to a temporary suspension of its stock [31] - Victory Energy's stock will resume trading after completing a verification process [32] Group 11 - China Merchants Industry has signed a shipbuilding agreement with Dalian Shipbuilding [33] - Kunyu Group has appointed a new chairman following a board meeting [34] - Microchip Bio's clinical trial application for a new diabetes treatment has been accepted [35] Group 12 - Hanshuo Technology has signed a sales intention agreement for smart shopping carts with Woolworths in Australia [36] - Zhongmin Energy's three photovoltaic power station projects have been included in the Fujian Province development list [37] - Penghui Energy plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [38] Group 13 - Victory Energy reports that the acquirer has deposited a guarantee for the acquisition [39] - Fangsheng Pharmaceutical proposes a special dividend of 0.15 yuan per share for 2025 [40] - Nanning Department Store has received approximately 14.28 million yuan in government subsidies since January 2025 [41] Group 14 - Jushen Co. has signed a bauxite transfer agreement with a company in Guinea [42] - ST Huluwawa has received a drug registration certificate for a new inhalation solution [43] - Zhongzhi Co. will become the controlling shareholder following a share transfer agreement [44] Group 15 - Chuangli Group has signed a strategic cooperation framework agreement with Chuanjiu Construction [45]

Core Viewpoint - The approval of the drug Eivocase tablets by the National Medical Products Administration is expected to enhance the company's product portfolio and market competitiveness, although future sales remain uncertain [1] Group 1: Regulatory Approvals - The subsidiary Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. received the drug registration certificate for Eivocase tablets [1] - The subsidiary Jiangsu Jiayi Pharmaceutical Co., Ltd. received the approval notice for the listing application of Eivocase as a chemical raw material drug [1] Group 2: Product Indication and Market Impact - Eivocase tablets are indicated for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis and are classified as a Category B product in the national medical insurance catalog [1] - The approval of this drug is anticipated to enrich the company's product structure and enhance its market competitiveness [1]

Core Viewpoint - The approval of the drug Eivocase tablets by the National Medical Products Administration is a significant milestone for Qianyuan Pharmaceutical, enhancing its product portfolio and market competitiveness, although future sales remain uncertain [1] Company Summary - Qianyuan Pharmaceutical's subsidiary, Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd., received the drug registration certificate for Eivocase tablets [1] - Another subsidiary, Jiangsu Jiayi Pharmaceutical Co., Ltd., obtained the approval notice for the listing application of Eivocase as a chemical raw material drug [1] - Eivocase tablets are indicated for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis and are classified as a Category B product in the national medical insurance catalog [1] Industry Summary - The approval of Eivocase tablets is expected to enrich the company's product structure and enhance its competitiveness in the pharmaceutical market [1] - The future sales performance of Eivocase tablets is subject to uncertainty, reflecting potential challenges in market acceptance and competition [1]

证券代码：300254 证券简称：仟源医药 公告编号：2026-001 关于子公司获得药品注册证书及化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，山西仟源医药集团股份有限公司（以下简称"公司"）之子公司杭州 仟源保灵药业有限公司收到国家药品监督管理局签发的"依伏卡塞片（1mg、2mg）" 《药品注册证书》，子公司江苏嘉逸医药有限公司收到国家药品监督管理局签发 的依伏卡塞《化学原料药上市申请批准通知书》。现将相关情况公告如下： 山西仟源医药集团股份有限公司 一、《药品注册证书》基本信息 药品通用名称：依伏卡塞片 剂型：片剂 规格：1mg、2mg 注册分类：化学药品4类 化学原料药注册标准编号：YBY73182025 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 申请事项：药品注册（境内生产） 药品批准文号：国药准字H20256430、国药准字H20256431 药品注册标准编号：YBH32962025 药品批准文号有效期：至2 ...

证券代码：300254 证券简称：仟源医药 公告编号：2025-075 山西仟源医药集团股份有限公司 关于董事、高级管理人员股份减持计划实施完毕的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 股东名称 | 减持方式 | | 减持期间 | 减持均价 （元/股） | 减持股数 （股） | 减持股份占总 股本比例（%） | | --- | --- | --- | --- | --- | --- | --- | | 虞英民 | 集中竞价 方式 | 2025 年 | 9 月 29 日 | 10.40 | 10,000 | 0.0039 | | 俞俊贤 | | | | 未减持 | | | | 顾宝平 | | | | 未减持 | | | | 贺延捷 | | | | 未减持 | | | | 罗开瑞 | | | | 未减持 | | | | | | 合 计 | | | 10,000 | 0.0039 | 3、股东本次减持前后持股情况 | 股东 | 股份性质 | 本次减持前持有股份 | | 本次减持后持有股份 | | | --- | --- | --- | --- | ...

（编辑 任世碧） 证券日报网讯 11月28日晚间，仟源医药发布公告称，公司注册地址变更为：山西省大同经济技术开发 区生物科技创新产业园翠微街2号，2025年限制性股票激励计划授予登记完成及2024年限制性股票激励 计划部分限制性股票回购注销导致注册资本变更，上述事项已分别经公司2025年第三次临时股东会以及 2025年第四次临时股东会审议通过。近日，公司已完成上述事项的工商变更登记手续，取得了由大同市 行政审批服务管理局换发的《营业执照》。 ...